All hospital visitors required to be vaccinated or have a negative COVID-19 test.

  • Inpatients in our Christiana, Wilmington and Union hospitals may have one visitor daily between 10 a.m. and 8 p.m. The visitor must be 16 or older.
  • Patients having outpatient surgery may have one support person accompany them. Support persons must be 16 or older.
  • All visitors and surgical support people must show proof of vaccination OR a negative COVID-19 test within the prior 72 hours.

Before visiting, click here for more details about visitation.

Visit or for local vaccination and testing sites.

All visitors are required to wear masks.

For COVID-19 safety, all visitors to ChristianaCare facilities and services are required to wear masks. This includes visitors who are vaccinated. Please read our visitor guidelines before arrival.

Clinical Trials

Cardiovascular Clinical Trials

New studies are looking at ways to lower the risks of heart disease and stroke from just about every angle. Here are a few examples of the many Cardiovascular Research clinical trials in progress and open for enrollment. For more information call 302-733-2658.

Study title ZEUS: Testing a new cardiac imaging agent—Open-Label, Phase 2 Study of the Safety and Efficacy of ß-Methyl-p-[123I]-Iodophenyl-Pentadecanoic Acid (Iodofiltic Acid I 123) for Identification of Ischemic Myocardium Using Single Photon Emission Computed Tomography (SPECT) in Adults with Symptoms Consistent with Acute Coronary Syndrome (ACS)
Principle investigator Timothy Manzone, M.D.
Description An investigational drug (iodofiltic acid I-123) is being tested to help detect heart injury sooner in patients who come to the emergency department with chest pain. Current methods used to evaluate chest pain in the emergency department, including electrocardiograms and blood tests, do not provide enough information quickly to know if there has been any heart injury. Heart pictures taken with iodofiltic acid I-123, using a nuclear medicine technique called single photon emission computed tomography (SPECT), will be compared to the final results of all the patient’s tests to determine if the investigational drug is useful in detecting heart problems sooner than what is currently available.
Study title Precision Study: Is one type of arthritis drug better for patients with cardiovascular disease?
Principle investigator Arthur Colbourn, M.D.
Co-investigators Mark Zolnick, M.D. and Michael Stillabower M.D.
Description Patients who have coronary heart disease or multiple risk factors are the focus of this worldwide study comparing the safety and efficacy of Celebrex (a COX-2 inhibitor) to Motrin (Ibuprofen) or Aleve (Naproxen), both of which are non-steroidal anti-inflammatory drugs or NSAIDs.. Participants will be randomized to receive one or the other of the study drugs to treat their symptoms of osteoarthritis, the most common form of arthritis. Patients with rheumatoid arthritis will also be included in the study.
Study title AIM-HIGH Study: Can two drugs work better than one to promote healthy cholesterol?
Principle investigator Edward Goldenberg, M.D.
Co-investigators John Kelly, M.D., Michael Stillabower, M.D., and James Lenhard, M.D.
Description This study is comparing ZOCOR, a popular cholesterol medication, when taken alone or in combination with extended release niacin to lower the occurrence of heart attacks and stroke. Niacin has the ability to raise good cholesterol (HDL-C) and also may improve total cholesterol by reducing bad cholesterol (LDL-C) and triglycerides. Niacin also exhibits antioxidant, anti-inflammatory and other beneficial effects that could slow the processes that lead to blocked arteries that can cause heart attacks or strokes.
Study title PLATO Study: Testing a new drug to stop dangerous blood clots
Principle investigator Andrew Doorey, M.D.
Co-investigators James Hopkins, M.D., Gilbert Leidig, M.D., and Michael Stillabower, M.D.
Description Patients who have had a heart attack or who experience very severe chest pain are at high risk for forming blood clots and are often prescribed blood thinners such as clopidogrel (PLAVIX). This study is being carried out to see if an investigational medicine, called AZD6140, works as well or better than PLAVIX in stopping the formation of new blood clots.